As the RAF pathway is well-established as being involved in intracellular signaling for cell growth and differentiation by activating the MEK-ERK axis, BRAF somatic mutations, even if uncommon in CRC samples (4–15%), have promise as predictive markers of resistance to anti-EGFR therapy. The gene discussed is BRAF; the disease is colorectal carcinoma.